Innovative Approaches for Diagnosing NAFLD and NASH: Moving Beyond Liver Biopsy

Type of Article: Original Article

Topic: Chronic kidney disease associated with hypertension

First author: Umair Khan
Master Student of Xinjiang Medical University
(Department of Endocrinology)
Address:Xinyi Road, Urumqi, Xinjiang, China

Contact number: +86 17590823420
E-mail ID umairkhan34719@gmail.com

Corresponding author: Professor Du Guo Li
Xinjiang Medical University First Affiliated Hospital
(Department of Endocrinology)
Address: Xinyi Road, Urumqi, Xinjiang, China
E-mail ID genemagic@126.com
Contribution: Supervisor

Second author: Ayiguzhali Abulitipu
Master Student of Xinjiang Medical University
(Department of Endocrinology)
Address: Xinyi Road, Urumqi, Xinjiang, China

E-mail ID 569249253@qq.com

Third author: Syed Muhammad Ali
Master Student of Xinjiang Medical University
(Department of Nephrology)
Address: Xinyi Road, Urumqi, Xinjiang, China
Contact number:
E-mail ID drsyedmuhammadali912@gmail.com

Fourth author: Doctor Sadia Hassan
Department of General Surgery, DHQ hospital, Hunza, Gilgit Pakistan

E-mail ID sadia_hassan0987@yahoo.com

Fifth author: Saddam Hussain

Master Student of Xinjiang Medical University
(Department of Cardiology)
Address: Xinyi Road, Urumqi, Xinjiang, China
Contact number: +8617590820604
E-mail ID maverick777@qq.com

Sixth author: Yangmin Hao
Master Student of Xinjiang Medical University
(Department of Endocrinology)
Address: Xinyi Road, Urumqi, Xinjiang, China

E-mail ID 745494432@qq.com

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent and escalating liver condition linked to the global rise in obesity, type 2 diabetes, and metabolic syndrome. NAFLD encompasses a spectrum of liver disorders, ranging from Non-Alcoholic Fatty Liver (NAFL), characterized by liver fat accumulation without significant inflammation, to the more severe Non-Alcoholic Steatohepatitis (NASH), which includes inflammation and liver cell injury, potentially leading to fibrosis and cirrhosis. Accurate differentiation between NAFL and NASH is crucial for prognosis and treatment.

Various diagnostic approaches have been explored, including blood and serum tests assessing steatosis, steatohepatitis, and fibrosis. Imaging techniques such as ultrasound, elastography, and Magnetic Resonance Imaging (MRI) offer non-invasive alternatives, while genetic tests reveal important risk factors. Notably, emerging research highlights the role of exosomes, adipose tissue, and gut microbiota in NAFLD pathogenesis.

Despite advancements, NAFLD diagnosis remains a complex challenge, requiring a combination of clinical, biochemical, imaging, and genetic approaches. Identifying high-risk populations and understanding the interplay of contributing factors is essential for early intervention and effective management of this growing public health concern.

Introduction

Non-Alcoholic Fatty Liver Disease, commonly referred to as NAFLD, is a prevalent and increasingly recognized liver condition that has emerged as a significant public health concern[1]. NAFLD represents a spectrum of liver disorders characterized by the accumulation of excess fat in the liver cells, a phenomenon not directly attributed to alcohol consumption[1]. This condition has garnered attention due to its association with the rising global epidemics of obesity, type 2 diabetes, and metabolic syndrome[1, 2].

NAFLD is now considered one of the most common chronic liver diseases worldwide, with its prevalence mirroring the escalating rates of obesity and metabolic disorders[1]. While exact statistics vary by region, it is estimated that up to a quarter of the global population may be affected by NAFLD[3]. In certain high-risk populations, such as those with obesity and type 2 diabetes, the prevalence can be even higher[2]. This widespread prevalence underscores the importance of understanding and addressing NAFLD's implications for public health.

NAFLD encompasses a spectrum of conditions, ranging from the relatively benign accumulation of fat in the liver, known as Non-Alcoholic Fatty Liver (NAFL), to a more severe and potentially progressive form, known as Non-Alcoholic Steatohepatitis (NASH)[4]. In NAFL, the liver fat buildup occurs without significant inflammation or damage to liver cells[4]. However, NASH is characterized by the presence of inflammation and liver cell injury,

which can lead to fibrosis (scarring) of the liver[4]. Advanced fibrosis can result in cirrhosis and an increased risk of liver cancer[5]. The ability to differentiate between NAFL and NASH and assess the degree of fibrosis is crucial for prognosis and treatment decisions[5].



Risk Factors and Etiology

The precise cause of NAFLD is multifactorial and not fully understood. However, several key risk factors and contributing factors have been identified, including:

1. Obesity: Excess body weight, especially visceral adiposity (fat around the abdomen), is a primary risk factor for NAFLD.
2. Insulin Resistance: Impaired insulin sensitivity and metabolic abnormalities play a central role in the development of NAFLD.
3. Type 2 Diabetes: Individuals with diabetes are at an increased risk of NAFLD.
4. High Blood Pressure: Hypertension is often associated with NAFLD.
5. Genetics: Genetic factors may influence an individual's susceptibility to NAFLD.
6. Dietary Habits: Diets high in saturated fats, sugars, and processed foods are associated with an elevated risk.
7. Sedentary Lifestyle: Lack of physical activity contributes to the development and progression of NAFLD.

Diagnosis and Management

Diagnosis of NAFLD involves a combination of medical history assessment, physical examination, blood tests, and imaging studies. Liver biopsy, while less commonly performed today, may be necessary in some cases to assess the degree of liver damage. Early detection is vital, as it allows for interventions aimed at preventing or slowing disease progression.

The management of NAFLD primarily revolves around lifestyle modifications, including:

1. Weight loss: Even modest weight reduction can lead to significant improvements in liver health.
2. Diet: A balanced, low-fat, low-sugar diet is essential, as well as limiting processed foods and sugary beverages.
3. Exercise: Regular physical activity improves insulin sensitivity and aids in weight management.

4. Medications: In certain cases, medications may be considered to address specific aspects of NAFLD or associated metabolic conditions.
5. Monitoring: Routine follow-up with healthcare providers is essential to track liver function and assess disease progression.

Non-Alcoholic Fatty Liver Disease is a complex and multifaceted liver condition that has become a major global health concern. With its strong associations with obesity, diabetes, and metabolic syndrome, understanding NAFLD's etiology, risk factors, and management strategies is paramount in addressing its impact on public health. Early diagnosis, lifestyle modifications, and ongoing medical management are crucial elements in mitigating the progression of NAFLD and its potential complications.

Types of NAFLD

Non-Alcoholic Fatty Liver Disease (NAFLD) encompasses a spectrum of liver conditions, with the two primary types being Non-Alcoholic Fatty Liver (NAFL) and Non-Alcoholic Steatohepatitis (NASH)[6]. These two types represent different stages of the disease, varying in severity and clinical characteristics. Here's an overview of these two main types:

1. Non-Alcoholic Fatty Liver (NAFL):

- NAFL is the milder and more common form of NAFLD[7].
- In NAFL, there is an accumulation of excess fat (steatosis) in the liver cells, but there is minimal or no inflammation and liver cell damage[7].
- NAFL is often considered a relatively benign condition, as it may not progress to more severe liver disease in many individuals[6].
- However, NAFL can progress to NASH in some cases, especially if risk factors persist or worsen[8].

2. Non-Alcoholic Steatohepatitis (NASH):

- NASH is the more advanced and potentially serious form of NAFLD[9].
- In NASH, there is not only the accumulation of fat in the liver cells but also inflammation and liver cell injury[9].
- NASH is associated with a higher risk of liver fibrosis (scarring), which can progress to cirrhosis and increase the risk of liver cancer[9].
- Unlike NAFL, NASH can lead to more significant liver-related complications, and it requires closer monitoring and medical intervention[9].

It's important to note that NAFLD is not limited to these two categories alone, as it is a complex disease with various factors at play. The disease progression can vary from person to person, and some individuals may fall somewhere between NAFL and NASH on the disease spectrum. Additionally, the degree of liver fibrosis can also vary, and identifying the stage of fibrosis is critical for assessing the prognosis and determining treatment strategies[10].

Beyond NAFL and NASH, there are subcategories and variations in NAFLD research and classification, but they are typically used for research purposes and may not have a direct impact on clinical management[10]. Some researchers may further categorize NASH based on the severity of fibrosis (e.g., F1 to F4 stages) or use more specialized tools like non-invasive imaging and blood tests to assess liver health.

Parameters	Non-Alcoholic Fatty Liver (NAFL)	Non-Alcoholic Steatohepatitis (NASH)
Definition	A condition where there is a mainly harmless build-up of fat in the liver.	A condition where there is fat in the liver along with inflammation and liver cell damage.
Symptoms	Usually asymptomatic. If symptoms do occur, they may include fatigue,	Similar to NAFL, NASH is often a silent disease with few or no

	enlarged liver, pain in the upper right abdomen, ascites, jaundice, and enlarged spleen.	symptoms. If symptoms do occur, they may include abdominal pain, fatigue, jaundice, loss of appetite, mental confusion, nausea, swelling in the legs and abdomen, weakness, and weight loss.
Causes	The cause is not clearly understood. It is associated with obesity, insulin resistance, hyperglycemia, high levels of fat in blood.	Similar to NAFL, the causes of NASH are not fully understood. It is often associated with conditions like obesity, metabolic syndrome, and type 2 diabetes.
Diagnosis	Diagnosed through medical history, a physical exam, and tests such as liver function tests, lipid profile test, ultrasound, transient elastography, magnetic resonance elastography (MRE), and liver biopsy.	Similar to NAFL, NASH is diagnosed through medical history, a physical exam, and tests such as blood tests, imaging tests, and liver biopsy.
Treatment	No specific treatment. It involves treating underlying conditions such as obesity. Weight loss can help reduce fat in the liver.	Similar to NAFL, weight loss is recommended for treating NASH. It can reduce fat, inflammation, and fibrosis in the liver3. Currently, no medicines have been approved to treat NASH.



NASH

Non-alcoholic steatohepatitis (NASH) is a chronic and progressive liver condition characterized by the accumulation of fat in the liver (steatosis) and inflammation[9]. NASH represents a more advanced stage of non-alcoholic fatty liver disease (NAFLD), a term used to describe the presence of excess fat in the liver among

individuals who consume minimal to no alcohol[9]. The precise cause of the transition from NAFLD to NASH remains unclear and is likely the result of a complex interplay of genetic and environmental factors[4]. Nonetheless, certain health conditions, including obesity, hypertension, and diabetes, elevate the risk of its development. Recent research has also suggested various genetic, epigenetic, and environmental factors as potential contributors to NAFLD and NASH, including factors like smoking and alterations in copper availability[4].

NASH is frequently mischaracterized as an asymptomatic ailment, as it often presents with non-specific symptoms like fatigue or discomfort in the upper right abdomen[11]. Consequently, the disease can advance unnoticed, making it challenging to determine its exact prevalence[11]. However, the burden of NASH is on the rise, coinciding with the increasing rates of obesity and NAFLD[11]. It is estimated that approximately one-third of NAFLD patients progress to NASH, translating to around 5% of the UK's population alone[12]. NASH has the potential to progress to liver fibrosis, affecting roughly 20% of all NASH patients, particularly in the form of bridging fibrosis (F3) or cirrhosis (F4)[13]. Advanced fibrosis significantly heightens the disease burden in NASH, leading to end-stage liver disease, hepatocellular cancer (HCC), the necessity for liver transplantation, and even mortality[13]. The degree of underlying fibrosis plays a critical role in determining clinical outcomes and the risk of mortality, as advanced fibrosis independently predicts overall and disease-specific mortality.



Despite the increasing prevalence of NASH, effective non-invasive diagnostic tests for the condition remain lacking. Presently, liver biopsy is often considered the gold standard for diagnosis, despite its associated challenges, such as accuracy, patient acceptance, safety, and cost. Moreover, given its intricate nature and diagnostic difficulties, there are currently no approved therapies for NASH. Therefore, understanding the epidemiology and burden of NASH is essential for establishing clear guidelines for early detection and effective therapeutic strategies.

Current Detailed Diagnostic Approaches

Various imaging and clinical factors can suggest NASH, but invasive liver biopsies remain the gold standard, despite drawbacks like invasiveness and late diagnoses due to NAFLD's usual asymptomatic nature[14]. Researchers differ on the need to distinguish benign fatty liver from NASH[14]. NAFLD's complexity and

heterogeneity contribute to this debate. About 20-30% of NAFLD patients progress to NASH-fibrosis, emphasizing the need for noninvasive early diagnostic methods. Less common conditions can mimic NAFLD/NASH[15]. Primary NAFLD causes include obesity, diabetes, dyslipidemia, and genetics. Secondary causes encompass lipid disorders, parenteral nutrition, hepatitis C, weight loss surgery, medications, starvation, Wilson's disease, toxins, and celiac disease[15].

Metabolic syndrome-linked issues like obstructive sleep apnea (OSAS), polycystic ovary syndrome (PCOS), and non-obese NAFLD also contribute. OSAS, often with obesity, induces chronic hypoxia and inflammation[16]. PCOS, a common endocrine disorder in women, is associated with obesity, dyslipidemia, insulin resistance, type 2 diabetes, and inflammation[17]. NAFLD can affect non-obese individuals with metabolic abnormalities, termed "metabolically obese but normal weight" (MONW)[18]. MONW patients may have risk factors like dysfunctional fat, reduced muscle, genetics, distinct gut microbiota, and early-life epigenetic changes[18].To avoid diagnostic pitfalls between traditional metabolic NAFLD and secondary causes, comprehensive patient evaluations are crucial. These distinct conditions necessitate different treatments.

This review outlines the current screening techniques employed to enhance our understanding of NAFLD/NASH and offers insights into potential emerging alternatives that could eliminate the necessity for liver biopsies.

Blood and Serum Tests

Liver biopsy remains the NASH diagnostic standard. Despite the surgical risk, it's limited by sampling bias and potential disease severity underestimation. Hence, a pressing need for reliable, less invasive biomarkers[19]. However, NAFLD/NASH's multifactorial nature makes a single surrogate marker insufficient for predicting outcomes or treatment benefits. While all biomarkers and scores have limitations, growing interest in their use for disease progression and outcome prediction exists[20]. Careful utilization of market-offered surrogate biomarkers and scores, proven robust in disease management, is crucial.

Additionally, standardization improvements for these methods are urgently needed. Surrogate markers can be valuable when used correctly, as shown in a study combining telemedicine-based comprehensive care, carbohydrate restriction-induced ketosis, and behavior changes. This study revealed reduced NAFLD liver fat scores (N-LFS) in the intervention group, highlighting surrogate markers' potential for measuring therapy efficacy[20].

In this summary, we'll discuss available blood and serum biomarkers, assessing their advantages and limitations in NASH and NAFLD diagnosis and management.

1. **Steatosis**

   Hepatic steatosis, a key NAFLD feature, is diagnosed when over 5% of hepatocytes contain fat or when intrahepatic triglycerides exceed 5.5% without prior liver disease[6]. No specific serum marker for hepatic steatosis exists, but multiple reproducible blood biomarker panels assess NAFLD. These panels comprise markers for liver damage (AST, ALT, bilirubin, γ-GT, platelet count, haptoglobin), lipid disorders (cholesterol, triglycerides), diabetes (HbA1c, fasting insulin), inflammation (α2M, ferritin), and matrix turnover (TIMP-1, PIIINP, HA)[6].

   The NAFLD ridge score is one efficient panel with an AUROC accuracy of 0.87, including ALT, HDL cholesterol, triglycerides, HbA1c, leukocyte count, and hypertension presence[21]. It has a 96% negative predictive value but can't differentiate steatosis grades or track changes over time. The NAFLD Liver Fat Score (NLFS), calculated quantitatively, incorporates liver fat (H-MRS), metabolic syndrome, type 2 diabetes, AST, AST:ALT ratio, and fasting insulin, offering 86% sensitivity and 71% specificity for >5.56% liver fat[21].The Hepatic Steatosis Index (HIS), including AST/ALT ratio, BMI, diabetes, and sex, yields 66% sensitivity and 69% specificity. The fatty liver index (FLI) combines BMI, waist circumference, triglycerides, and γ-GT, correlating with insulin resistance[22].

The lipid accumulation product index (LAP) accounts for sex, serum triglycerides, and waist circumference to assess lipid overaccumulation. In cross-sectional NAFLD cohorts, NLFS emerges as the best predictor with an AUC of 0.771[23]. However, these scores have limitations—they can't distinguish between steatosis grades or track changes over time[23].



2. Steatohepatitis

Transitioning from simple hepatic steatosis to NASH marks a critical stage in severe liver disease development, raising fibrosis and end-stage liver disease risks. Precise NASH diagnosis and tracking NAFLD-to-NASH changes remain ongoing challenges. Current diagnosis relies heavily on liver biopsy but suffers from pathologist variability. The FLIP algorithm, by Bedossa et al., standardizes scoring based on histological steatosis, disease activity, and fibrosis[24].

A novel machine learning approach, developed by Canbay and colleagues, differentiates NAFLD (NAS ≤ 4) from NASH (NAS ≥ 4) using age, HbA1c, γ-GT, adiponectin, and apoptosis marker M30. The CHeK score (http://CHek.heiderlab.de) detects NASH, tracks NAFLD-to-NASH progression and aids long-term patient monitoring during disease or therapy. Beyond histological scoring, the transition from NAFLD to NASH involves various molecular, cellular, and hormonal changes[25]. While cytokeratin 18 (CK18), a well-studied blood biomarker, indicates hepatocyte death through apoptosis and necroptosis in NASH compared to NAFLD, its sensitivity for NASH prediction is 66%, with specificity at 82%[26]. Combining CK18 with the apoptosis-mediating surface antigen FAS (sFAS) enhances accuracy, but optimal cutoff values vary across studies[26].NASH primarily involves glucose and lipid metabolism alterations, including adipokines (leptin, adiponectin, resistin) and liver-derived lipid hormones like fibroblast growth factor 21 (FGF21), linked to hepatic steatosis, intrahepatic triglyceride accumulation, and liver damage[27]. However, specificity varies due to factors like inflammation.

Inflammatory markers, including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukins (IL-6, IL-8), rise in NASH but lack diagnostic significance due to insensitivity to NASH-specific inflammatory changes. FOXA1, a transcription factor, may serve as a sensitive biomarker for liver fat accumulation, mitochondrial membrane potential, and reactive oxygen species (ROS) production[28]. However, FOXA1 isn't secreted into the serum[28]. Oxidative stress, a key NASH mechanism, leads to lipid

oxidation and inflammation. The oxNASH score, considering the linoleic acid:13-hydroxyoctadecadienoic acid (13-HODA) ratio, age, BMI, and AST level, achieved diagnostic accuracy (AUROC 0.74–0.83) but relies on mass spectrometry[29]. Insulin-like growth factor binding protein 1 (IGFBP-1) may be a serum marker for NAFLD and related fibrosis but could also relate to metabolic syndrome and insulin resistance[30].

Elevated ferritin levels, seen in NAFLD and metabolic syndrome patients, are independently associated with higher steatosis grades, NASH, and NASH fibrosis, improving accuracy when combined with AST, BMI, type 2 diabetes, hypertension, and platelet count[31].

In sum, despite efforts, many biomarkers and panels require further validation across diverse patient cohorts. Standardizing cut-off values and conducting extensive research to comprehend NAFLD's underlying mechanisms are crucial for advancing the diagnosis and monitoring of this complex disease.



3. Fibrosis

The F2 fibrosis stage is a crucial point in the progression from NASH to end-stage liver disease, emphasizing the need for therapeutic intervention. Liver-specific mortality risk rises by 50–80% at stages F3 and F4 fibrosis, highlighting the importance of noninvasive diagnosis and monitoring.

Most biomarkers indirectly assess fibrogenesis or fibrinolysis, lacking accuracy. Combining clinical parameters in panels enhances reliability in distinguishing fibrosis stages. Common scores include NAFLD Fibrosis Score (NFS), Fibrosis-4 Score (FIB-4), AST to Platelet Ratio Index (APRI), and BARD Score, incorporating BMI, AST:ALT ratio, and diabetes (http://www.nafldscore.com/).NFS, considering parameters like AST:ALT ratio, albumin, platelet count, age, BMI, and hyperglycemia, offers high predictive value for fibrosis, potentially avoiding liver biopsies, but has dual cutoff levels causing classification issues.

FIB-4, relying on AST, ALT, platelet count, and age, exhibits an AUROC of 0.86 for advanced fibrosis, with high negative predictive value (>90%) but dual cutoffs (<1.45 for moderate, >3.25 for advanced fibrosis) [88]. Both NFS and FIB-4 can predict decompensation[32].

APRI calculates the AST/platelet ratio but lacks accuracy (AUROC 0.788). Despite its simplicity, it's less accurate for predicting advanced fibrosis. The BARD Score, incorporating type II diabetes, BMI, and AST:ALT ratio, detects F3 fibrosis (AUROC 0.81), with a high negative predictive value (96%) but a modest positive predictive value[33]. The MACK-3 score, including HOMA insulin resistance, AST, and CK18 serum level, shows promise with an AUROC of 0.80 and a 100% negative predictive value for fibrotic NASH[33, 34].

Existing scores have moderate sensitivity, urging further noninvasive marker investigation. Serum-specific fibrosis biomarkers, such as hyaluronic acid, PIIINP[35], type IV collagen, TIMP-1[36], or laminin, have strong AUROCs but aren't widely used due to cost and complexity. Complex algorithms like the Enhanced Liver Fibrosis panel (ELF), Fibro-Test/Fibro-SURE/Acti-Test, Fibro-Meter NAFLD index, Hepa-score, and others hold promise for distinguishing fibrosis stages and need validation and simplification for broader application[37]. The Liver-Fibro-STARD checklist helps establish requirements for new noninvasive fibrosis markers[38]. Yet, predicting NASH severity through noninvasive markers, scores, tests, or algorithms may not comprehensively determine disease outcome, as various factors and comorbidities influence NASH progression, as shown in a study linking copper bioavailability to atherosclerosis in hepatic steatosis patients. Reduced hepatic copper concentrations were also associated with greater hepatic steatosis in rats on low copper diets[39].



Imaging

Histological liver biopsy, serum marker-based values, and body measurements help assess inflammation and fibrosis but have limitations. Liver biopsy is invasive, costly, and prone to complications like bleeding and infections. It's also observer-dependent and may not represent the entire organ. Monitoring fibrosis changes requires repeated biopsies, impractical for routine use. Biomarkers, single or combined, that meet diagnostic criteria are lacking due to reference test absence and analytical variability. As a result, they have limited clinical use. Imaging techniques offer direct liver health insights, serving as attractive NASH and NAFLD diagnostic alternatives. Here, we summarize imaging-based methods.

1. **Ultrasound**

   In 1981, ultrasonography was first used to diagnose hepatic steatosis and steatohepatitis in alcohol-related disease patients, assessing parenchymal changes, fatty infiltration, hepatic vein dilatation, and ascites. Subsequent studies revealed its sensitivity limitation for lower hepatic steatosis levels[40]. However, a prospective study with 400 patients demonstrated that ultrasonography revealed higher NAFLD and NASH prevalence than originally thought, especially in patients with elevated liver enzymes. A recent cross-sectional study categorized 109 patients by ultrasound, confirming its importance for diagnosing and grading fatty liver diseases, making it a valuable, cost-effective, and side-effect-free tool for patient management[37].

   Furthermore, contrast-enhanced ultrasound (CEUS) enables both qualitative and quantitative analysis of lesion microcirculation, aiding in diagnosing focal and diffuse liver conditions and distinguishing between benign and malignant liver lesions.

2. **Ultrasound-Based Elastography Techniques**

   In 2005, it was shown that real-time low-frequency pulsed shear waves in biological tissue correlate with the extracellular matrix amount[41]. Methods based on shear wave velocity, such as "transient elastography," "vibration-controlled transient elastography (VCTE)," or "real-time shear wave elastography (SWE)," are effective for detecting high-stiffness liver cirrhosis, with a diagnostic specificity of 99%[42]. Notably, point-of-care testing, like the FibroScan by Echosens SA, offers immediate results for care providers and patients. However, technical limitations exist for patients with ascites, significant chest wall fat, or morbid obesity.

   Acoustic radiation force impulse elastography (ARFI), which measures a standardized liver region, overcomes limitations related to obesity and ascites but may perform poorly in individuals with a BMI above 35 kg/m^2[43]. Other real-time ultrasound methods for tissue elasticity mapping, such as SWE and supersonic shear imaging (SSI), quantitatively map tissue elasticity by analyzing wave propagation in video clips[44]. While these methods are effective for hepatitis B-related fibrosis staging, their performance in other liver diseases is still under investigation[44].

   In certain conditions, combining elastography techniques with specific NAFLD scores based on patient characteristics and clinical chemistry parameters can enhance accuracy in assessing clinically significant liver fibrosis in NAFLD. This combination has the potential to better identify patients who require a liver biopsy.

3. **Controlled Attenuation Parameter**

   The Controlled Attenuation Parameter (CAP), designed for the FibroScan device, was developed to identify hepatic steatosis in patients with approximately 10% fatty hepatocyte degeneration, regardless of liver fibrosis or cirrhosis influence. This threshold is clinically significant, as hepatic steatosis is typically diagnosed when hepatic lipid content exceeds 5-10% by weight[45]. The CAP signal's significant correlation with steatosis was first established in 2010[46]. This study demonstrated CAP's effectiveness in distinguishing between different steatosis grades, with AUROC values of 0.91 and 0.95 for detecting more than 10% and 33% of steatosis, respectively[46]. However, it's important to note that CAP increases after a meal across all fibrosis stages, potentially leading to misclassification if preanalytical requirements aren't followed by the operator.

4. **Magnetic Resonance Imaging in NASH and NAFLD**

   Magnetic Resonance Imaging (MRI) offers a non-ionizing radiation-based method for quantifying hepatic fat content with high spatial resolution. However, obtaining high-resolution MRI images typically requires

extended imaging times, which can be reduced by administering gadolinium (III)-based contrast agents intravenously[47]. Advanced MRI techniques, such as MRI Proton Density Fat Fraction (MRI-PDFF), were developed explicitly for detecting hepatic steatosis and assessing liver fat distribution across the entire organ[48]. PDFF is expressed as a percentage, ranging from 0% to 100%, representing the ratio of mobile protons from fat (i.e., triglycerides) to the total density of protons from both mobile triglycerides and mobile water[49]. Due to its robustness, practicality, and reproducibility, PDFF has been proposed as the most suitable quantitative MR-based biomarker for tissue fat concentration, suitable for large-scale research endeavors and widespread clinical use[48, 49]. Multiple independent studies focusing on NAFLD patients have demonstrated that MRI-PDFF outperforms CAP in diagnosing all steatosis stages and exhibits superior overall diagnostic accuracy.

5. **Magnetic Resonance Elastography**

   A meta-analysis of retrospective studies highlighted the effectiveness of Magnetic Resonance Elastography (MRE) in assessing liver stiffness, making it highly accurate for diagnosing significant fibrosis and cirrhosis[50]. This imaging method is valuable for monitoring disease progression and treatment response in chronic liver conditions, complementing ultrasound-based elastography techniques[22]. MRE's diagnostic precision for advanced fibrosis in NAFLD patients was evident in a prospective study comparing 3D-MRE and 2D-MRE in a cohort of 100 patients with confirmed NAFLD[51]. Notably, 3D-MRE outperformed 2D-MRE in identifying advanced fibrosis.

   In a cross-sectional study involving over 100 NAFLD patients, MRE exhibited greater accuracy than ultrasound-based transient elastography in detecting fibrosis, achieving an AUROC of 0.82 (95% confidence interval, 0.74–0.91)[51]. Additionally, MRE demonstrated superior diagnostic performance for classifying steatosis and necro-inflammatory activity compared to transient elastography in NAFLD patients[51].

Genetic Tests

Genome-wide association studies have shed light on genetic and genomic alterations in NASH development, uncovering potential therapeutic targets and risk predictors. Key alterations involve single nucleotide polymorphisms (SNPs) in genes like PNPLA3, TM6SF2, MBOAT7, and GCKR. PNPLA3 encodes adiponectin, a triacylglycerol lipase responsible for hydrolyzing triacylglycerol in adipocytes and hepatocytes. A prominent DNA sequence variation is the PNPLA3-148M variant, linked to NAFLD and NASH. This variant leads to triglyceride accumulation in hepatocytes and hepatic stellate cells, substantially increasing the risk of NAFLD-related HCC[52].

TM6SF2, expressed in the liver and small intestine, regulates triglyceride secretion and lipid droplet content. The E167K variant, a common SNP in TM6SF2, results in hepatocyte triglyceride buildup and reduced systemic lipoprotein levels. MBOAT7 harbors a variant causing a cysteine-to-threonine substitution, affecting phosphatidyl-inositol-containing arachidonic acid levels and elevating the risk of NAFLD, NASH, and related liver diseases[53]. The GCKR gene houses the P446L mutation, influencing de novo lipogenesis and hepatic glucose uptake regulation, contributing to NAFLD development. Beyond these, additional genetic polymorphisms in ethanol-metabolizing enzymes and CYP2E1 activation play roles in oxidative biotransformation and ROS production, affecting liver injury susceptibility in conditions like obesity[54].

Recent exploratory studies in preclinical models have identified circulating non-coding RNAs (ncRNA), including microRNAs and long ncRNAs, as involved in liver disease pathogenesis and progression. Profiling in NASH models identified specific microRNA signatures distinguishing NASH from healthy states. Clinical trials assessing their diagnostic and prognostic value in human liver diseases are ongoing, with more research needed[55].

Screening for NAFLD and NASH

Early identification of individuals at risk for NAFLD is crucial for timely intervention. Several early signs and symptoms can indicate NAFLD onset, including central obesity, elevated triglycerides, and impaired fasting glucose. Symptoms like anorexia, nausea, vomiting, malaise, headache, and abdominal pain can also suggest NAFLD initiation. Detecting risk in community healthcare settings is essential for preventing the progression of simple steatosis to severe NAFLD[56].

However, despite promising research on early biomarkers, most face limitations like low sensitivity, stability, and specificity. Additionally, diagnostic panel screenings are costly. The benign nature of NAFLD is questioned, further complicating diagnostic starting points. As a result, scientific societies like AASLD, EASL, NICE, and the Asia-Pacific Working Party either do not support NAFLD screening or recommend it only for high-risk groups[57].

Other Factors in NAFLD and NASH

Recent reports highlight the significant role of exosomes, which transport various cargoes, including proteins, fats, and nucleic acids, in liver pathobiology. While their precise contributions to NAFLD and NASH remain unclear, specific exosomal microRNAs like miR-192 released from injured hepatocytes are proposed as potential biomarkers for assessing the transition from simple steatosis to NASH[58]. Encouraging studies have sparked interest in developing exosomes as biomarker targets.

Researchers also investigate the involvement of adipose tissue in NAFLD, particularly the role of adipose tissue macrophages. Various signaling molecules, such as lipids, microRNAs, adipokines, and immune-related compounds, are released from adipose tissue into the portal vein, triggering hepatic inflammation[59]. Dysfunctional adipocytes release fatty acids, leading to liver cell toxicity and the accumulation of harmful metabolites, amplifying inflammatory pathways[59]. However, these mechanisms are not yet fully understood, and further studies are needed to explore the impact of different macrophage phenotypes on NAFLD and NASH development.

Another area of recent focus in NAFLD and NASH research is the quantitative and qualitative changes in intestinal flora, known as dysbiosis[60]. This dysbiosis can result from altered food metabolism, intoxication, or increased intestinal barrier permeability[60]. Emerging evidence suggests a crucial role for the gut microbiome in the pathogenesis of obesity and metabolic syndrome. The gut microbiota affects liver steatosis by modulating the processing of various molecules like short-chain fatty acids, bile acids, and choline[61]. Furthermore, discussions are ongoing regarding whether microbiome composition can serve as a biomarker to distinguish between NAFLD and NASH. However, standardized test systems and microbiota-targeted treatments for NAFLD and NASH are still under development[61].

Conclusion

In conclusion, Non-Alcoholic Fatty Liver Disease (NAFLD) and its more severe form, Non-Alcoholic Steatohepatitis (NASH), represent significant and growing public health challenges. These conditions are closely linked to the global epidemics of obesity, type 2 diabetes, and metabolic syndrome. The prevalence of NAFLD is alarmingly high, affecting up to a quarter of the global population, with even higher rates in certain high-risk groups.NAFLD encompasses a spectrum of conditions, ranging from the relatively benign Non-Alcoholic Fatty Liver (NAFL) to the more severe and potentially progressive NASH. Accurately diagnosing and differentiating between these stages is crucial for prognosis and treatment decisions, as NASH carries a higher risk of liver fibrosis, cirrhosis, and liver cancer. Current diagnostic approaches, such as liver biopsy, are invasive, expensive, and associated with various limitations. Emerging non-invasive methods offer promising alternatives. Blood and serum tests provide insights into steatosis, inflammation, and fibrosis. Imaging techniques, including ultrasound, magnetic resonance imaging (MRI), magnetic resonance elastography (MRE), and controlled attenuation parameter (CAP),

enable non-invasive assessment of liver health. Genetic tests and markers like PNPLA3 variants and circulating non-coding RNAs provide insights into genetic predisposition and molecular changes in NAFLD and NASH. Despite these advancements, challenges remain, including the need for further validation and standardization of non-invasive biomarkers and imaging techniques. Additionally, research into the role of exosomes, adipose tissue macrophages, and the gut microbiome in NAFLD and NASH is ongoing and holds promise for future diagnostics and therapeutic interventions. In clinical practice, a multi-faceted approach to NAFLD and NASH diagnosis is often necessary, combining clinical assessments, blood tests, imaging, and potentially genetic evaluations. Timely and accurate diagnosis is crucial for identifying patients at risk of disease progression and for developing effective treatment strategies. As our understanding of NAFLD and NASH continues to evolve, ongoing research and collaboration between healthcare providers, researchers, and policymakers are essential to address the growing burden of these liver conditions and improve the lives of affected individuals. Early detection, lifestyle interventions, and potential pharmacological treatments are essential components of the comprehensive approach needed to combat the NAFLD and NASH epidemic.

References

1. Powell, E.E., V.W.-S. Wong, and M. Rinella, Non-alcoholic fatty liver disease. The Lancet, 2021. **397**(10290): p. 2212-2224.
2. Mansour, A., M.R. Mohajeri-Tehrani, M. Samadi, H. Gerami, M. Qorbani, N. Bellissimo, H. Poustchi, and A. Hekmatdoost, Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetologica, 2019. **56**: p. 1199-1207.
3. Mitra, S., A. De, and A. Chowdhury, Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational gastroenterology and hepatology, 2020. **5**.
4. Ye, Q., B. Zou, Y.H. Yeo, J. Li, D.Q. Huang, Y. Wu, H. Yang, C. Liu, L.Y. Kam, and X.X.E. Tan, Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology, 2020. **5**(8): p. 739-752.
5. Bertot, L.C., G.P. Jeffrey, B. de Boer, G. MacQuillan, G. Garas, J. Chin, Y. Huang, and L.A. Adams, Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver International, 2018. **38**(10): p. 1793-1802.
6. Chalasani, N., Z. Younossi, J.E. Lavine, M. Charlton, K. Cusi, M. Rinella, S.A. Harrison, E.M. Brunt, and A.J. Sanyal, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018. **67**(1): p. 328-357.
7. Zhou, J., F. Zhou, W. Wang, X.J. Zhang, Y.X. Ji, P. Zhang, Z.G. She, L. Zhu, J. Cai, and H. Li, Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020. **71**(5): p. 1851-1864.
8. Younossi, Z., Q.M. Anstee, M. Marietti, T. Hardy, L. Henry, M. Eslam, J. George, and E. Bugianesi, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & hepatology, 2018. **15**(1): p. 11-20.
9. Peng, C., A.G. Stewart, O.L. Woodman, R.H. Ritchie, and C.X. Qin, Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Frontiers in Pharmacology, 2020. **11**: p. 603926.
10. Friedman, S.L., B.A. Neuschwander-Tetri, M. Rinella, and A.J. Sanyal, Mechanisms of NAFLD development and therapeutic strategies. Nature medicine, 2018. **24**(7): p. 908-922.
11. Doward, L.C., M.-M. Balp, J. Twiss, C. Slota, D. Cryer, C.A. Brass, Q.M. Anstee, and A.J. Sanyal, Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study. The Patient-Patient-Centered Outcomes Research, 2021. **14**: p. 533-543.
12. Younossi, Z., P. Aggarwal, I. Shrestha, J. Fernandes, P. Johansen, M. Augusto, and S. Nair, The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Reports, 2022. **4**(9): p. 100525.
13. Méndez-Sánchez, N., A. Valencia-Rodríguez, C. Coronel-Castillo, A. Vera-Barajas, J. Contreras-Carmona, G. Ponciano-Rodríguez, and D. Zamora-Valdés, The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis. Annals of Translational Medicine, 2020. **8**(6).
14. Wong, T., R.J. Wong, and R.G. Gish, Diagnostic and treatment implications of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gastroenterology & hepatology, 2019. **15**(2): p. 83.

15. Kneeman, J.M., J. Misdraji, and K.E. Corey, Secondary causes of nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2012. **5**(3): p. 199-207.
16. Nastasa, R., C. Stanciu, R. Nemteanu, and A. Trifan, Obstructive Sleep Apnea Syndrome and Nonalcoholic Fatty Liver Disease, in *Essentials of Non-Alcoholic Fatty Liver Disease: Complications and Extrahepatic Manifestations*. 2023, *Springer*. p. 217-227.
17. Salva-Pastor, N., N.C. Chavez-Tapia, M. Uribe, and N. Nuno-Lambarri, Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. The Journal of Steroid Biochemistry and Molecular Biology, 2019. **194**: p. 105445.
18. Gao, N., J. Deng, J. Wang, Z. Zhou, C. Yao, M. Zhou, X. Xing, Q. Wang, X. Lu, and H. Shi, The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease. Frontiers in Medicine, 2022. **9**: p. 1038475.
19. Ooi, G.J., A. Clouston, Y. Johari, W.W. Kemp, S.K. Roberts, W.A. Brown, and P.R. Burton, Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. Surgical Endoscopy, 2021. **35**: p. 1210-1218.
20. Vilar-Gomez, E., S.J. Athinarayanan, R.N. Adams, S.J. Hallberg, N.H. Bhanpuri, A.L. McKenzie, W.W. Campbell, J.P. McCarter, S.D. Phinney, and J.S. Volek, Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. BMJ open, 2019. **9**(2): p. e023597.
21. Atsawarungruangkit, A., P. Laoveeravat, and K. Promrat, Machine learning models for predicting non-alcoholic fatty liver disease in the general United States population: NHANES database. World Journal of Hepatology, 2021. **13**(10): p. 1417.
22. Castera, L., M. Friedrich-Rust, and R. Loomba, Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019. **156**(5): p. 1264-1281. e4.
23. Bedogni, G., H.S. Kahn, S. Bellentani, and C. Tiribelli, A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC gastroenterology, 2010. **10**: p. 1-8.
24. Bedossa, P. and F.P. Consortium, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology, 2014. **60**(2): p. 565-575.
25. Canbay, A., J. Kälsch, U. Neumann, M. Rau, S. Hohenester, H.A. Baba, C. Rust, A. Geier, D. Heider, and J.-P. Sowa, Non-invasive assessment of NAFLD as systemic disease—a machine learning perspective. PloS one, 2019. **14**(3): p. e0214436.
26. Arab, J.P., C. Hernandez-Rocha, C. Morales, J.I. Vargas, N. Solis, M. Pizarro, C. Robles, D. Sandoval, S. Ponthus, and C. Benitez, Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Gastroenterología y Hepatología (English Edition), 2017. **40**(6): p. 388-394.
27. Wu, L., L. Qian, L. Zhang, J. Zhang, J. Zhou, Y. Li, X. Hou, Q. Fang, H. Li, and W. Jia, Fibroblast growth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events. Journal of the American Heart Association, 2020. **9**(11): p. e015226.
28. Lau, H.H., N.H.J. Ng, L.S.W. Loo, J.B. Jasmen, and A.K.K. Teo, The molecular functions of hepatocyte nuclear factors–In and beyond the liver. Journal of hepatology, 2018. **68**(5): p. 1033-1048.
29. Hall, Z., Y. Chu, and J.L. Griffin, Liquid extraction surface analysis mass spectrometry method for identifying the presence and severity of nonalcoholic fatty liver disease. Analytical chemistry, 2017. **89**(9): p. 5161-5170.
30. Hagström, H., P. Stål, R. Hultcrantz, K. Brismar, and I. Ansurudeen, IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD–a pilot study. Scandinavian journal of gastroenterology, 2017. **52**(12): p. 1427-1434.
31. Ajmera, V., E.R. Perito, N.M. Bass, N.A. Terrault, K.P. Yates, R. Gill, R. Loomba, A.M. Diehl, B.E. Aouizerat, and N.C.R. Network, Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology, 2017. **65**(1): p. 65-77.
32. Cheah, M.C., A.J. McCullough, and G.B.-B. Goh, Current modalities of fibrosis assessment in non-alcoholic fatty liver disease. Journal of clinical and translational hepatology, 2017. **5**(3): p. 261.
33. Ampuero, J., R. Pais, R. Aller, R. Gallego-Durán, J. Crespo, C. García-Monzón, J. Boursier, E. Vilar, S. Petta, and M.-H. Zheng, Development and validation of hepamet fibrosis scoring system–a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clinical Gastroenterology and Hepatology, 2020. **18**(1): p. 216-225. e5.

34. Drescher, H.K., S. Weiskirchen, and R. Weiskirchen, Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cells, 2019. **8**(8): p. 845.
35. Vilar-Gomez, E. and N. Chalasani, Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Journal of hepatology, 2018. **68**(2): p. 305-315.
36. Yasmeen, S., U. Khan, G.M. Khan, and S.S. Fatima, Association of tissue inhibitor of metalloproteinase 2 with non-alcoholic fatty liver disease in metabolic syndrome. Archives of Physiology and Biochemistry, 2019. **125**(5): p. 441-446.
37. Boursier, J., M. Guillaume, V. Leroy, M. Irlès, M. Roux, A. Lannes, J. Foucher, F. Zuberbuhler, C. Delabaudière, and J. Barthelon, New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. Journal of hepatology, 2019. **71**(2): p. 389-396.
38. Mahady, S.E., P. Macaskill, J.C. Craig, G.L. Wong, W.C. Chu, H.L. Chan, J. George, and V.W. Wong, Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clinical Gastroenterology and Hepatology, 2017. **15**(9): p. 1453-1460. e1.
39. Aigner, E., M. Strasser, H. Haufe, T. Sonnweber, F. Hohla, A. Stadlmayr, M. Solioz, H. Tilg, W. Patsch, and G. Weiss, A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Official journal of the American College of Gastroenterology| ACG, 2010. **105**(9): p. 1978-1985.
40. Taylor, K., F.S. Gorelick, A.T. Rosenfield, and C. Riely, Ultrasonography of alcoholic liver disease with histological correlation. Radiology, 1981. **141**(1): p. 157-161.
41. Sandrin, L., M. Tanter, S. Catheline, and M. Fink, Shear modulus imaging with 2-D transient elastography. IEEE transactions on ultrasonics, ferroelectrics, and frequency control, 2002. **49**(4): p. 426-435.
42. Zeng, J., J. Zheng, Z. Huang, S. Chen, J. Liu, T. Wu, R. Zheng, and M. Lu, Comparison of 2-D shear wave elastography and transient elastography for assessing liver fibrosis in chronic hepatitis B. Ultrasound in medicine & biology, 2017. **43**(8): p. 1563-1570.
43. Jiang, W., S. Huang, H. Teng, P. Wang, M. Wu, X. Zhou, and H. Ran, Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ open, 2018. **8**(8): p. e021787.
44. Harrison, S.A., S. Gawrieh, K. Roberts, C.J. Lisanti, R.B. Schwope, K.M. Cebe, V. Paradis, P. Bedossa, J.M.A. Whitehead, and A. Labourdette, Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. Journal of hepatology, 2021. **75**(2): p. 284-291.
45. Xu, C., H. Li, and C.-K. Tang, Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications. Metabolism, 2022. **131**: p. 155180.
46. Reddy, J.K. and M. Sambasiva Rao, Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2006. **290**(5): p. G852-G858.
47. Weiskirchen, R. and F. Tacke, The role of radiologic modalities in diagnosing nonalcoholic steatohepatitis (NASH) and fibrosis. Current Hepatology Reports, 2018. **17**: p. 324-335.
48. Caussy, C., S.B. Reeder, C.B. Sirlin, and R. Loomba, Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology, 2018. **68**(2): p. 763-772.
49. Wang, X., D. Hernando, and S.B. Reeder, Sensitivity of chemical shift-encoded fat quantification to calibration of fat MR spectrum. Magnetic resonance in Medicine, 2016. **75**(2): p. 845-851.
50. Singh, S., S.K. Venkatesh, R. Loomba, Z. Wang, C. Sirlin, J. Chen, M. Yin, F.H. Miller, R.N. Low, and T. Hassanein, Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. European radiology, 2016. **26**: p. 1431-1440.
51. Park, C.C., P. Nguyen, C. Hernandez, R. Bettencourt, K. Ramirez, L. Fortney, J. Hooker, E. Sy, M.T. Savides, and M.H. Alquiraish, Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology, 2017. **152**(3): p. 598-607. e2.
52. Eslam, M., L. Valenti, and S. Romeo, Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of hepatology, 2018. **68**(2): p. 268-279.
53. Luukkonen, P.K., Y. Zhou, P.N. Haridas, O.P. Dwivedi, T. Hyötyläinen, A. Ali, A. Juuti, M. Leivonen, T. Tukiainen, and L. Ahonen, Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of hepatology, 2017. **67**(1): p. 128-136.

54. Ford, B.E., S.S. Chachra, K. Rodgers, T. Moonira, Z.H. Al-Oanzi, Q.M. Anstee, H.L. Reeves, J.M. Schattenberg, R.J. Fairclough, and D.M. Smith, The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326. Molecular Metabolism, 2023. **72**: p. 101722.
55. Roy, S., C. Trautwein, T. Luedde, and C. Roderburg, A general overview on non-coding RNA-based diagnostic and therapeutic approaches for liver diseases. Frontiers in pharmacology, 2018. **9**: p. 805.
56. Turchinovich, A., A. Baranova, O. Drapkina, and A. Tonevitsky, Cell-free circulating nucleic acids as early biomarkers for NAFLD and NAFLD-associated disorders. Frontiers in Physiology, 2018. **9**: p. 1256.
57. Leoni, S., F. Tovoli, L. Napoli, I. Serio, S. Ferri, and L. Bolondi, Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World journal of gastroenterology, 2018. **24**(30): p. 3361.
58. Hwang, S. and Y.M. Yang, Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases. Archives of Pharmacal Research, 2021. **44**(6): p. 574-587.
59. Korf, H., M. Boesch, L. Meelberghs, and S. van der Merwe. Macrophages as key players during adipose tissue–liver crosstalk in nonalcoholic fatty liver disease. in *Seminars in liver disease*. 2019. *Thieme Medical Publishers*.
60. Jayakumar, S. and R. Loomba, emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Alimentary Pharmacology & Therapeutics, 2019. **50**(2): p. 144-158.
61. Kolodziejczyk, A.A., D. Zheng, O. Shibolet, and E. Elinav, The role of the microbiome in NAFLD and NASH. EMBO molecular medicine, 2019. **11**(2): p. e9302.